Contrave for Weight Management: What the Trials Establish
Contrave produced more weight loss than placebo in pivotal trials, but tolerability, discontinuation, and unresolved cardiovascular outcomes matter.
Key takeaways
- Full maintenance dosing supplies 32 mg naltrexone and 360 mg bupropion daily.
- In COR-I, mean weight change at 56 weeks was about −6.1% with NB32 vs −1.3% with placebo in the prespecified analysis.
- About 48% vs 16% achieved at least 5% weight loss in that analysis.
- These averages do not predict individual response and depend on analysis population and adherence.
- The LIGHT cardiovascular trial was terminated early after inappropriate disclosure of interim results; it cannot establish cardiovascular safety.
- The FDA label explicitly says the effect on cardiovascular morbidity and mortality has not been established.
What Contrave is—and is not
Contrave is approved in the US as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in eligible adults. It is not addiction-treatment naltrexone. The combination, dose, titration, contraindications, boxed warning, and treatment goal are different.
Evidence at a glance
| Evidence | What it supports | Important limitation |
|---|---|---|
| COR-I | Greater mean weight loss and more 5% and 10% responders than placebo | High discontinuation and selected trial population; individual results vary |
| Other pivotal COR trials | Benefit across behavioural-treatment and type 2 diabetes settings | Different populations and co-interventions make simple pooling misleading |
| LIGHT | Interim cardiovascular data were collected | Early termination and disclosure compromised the trial; cardiovascular safety remains unresolved |
| FDA label | Approved indication, dosing, stop rule, contraindications, adverse effects | A label describes population-level evidence, not personal suitability |
The 16-week stopping rule
The US label instructs clinicians to evaluate response after 12 weeks at the maintenance dose—which corresponds to week 16 after the four-week titration. If at least 5% of baseline body weight has not been lost, Contrave should be discontinued because clinically meaningful weight loss is unlikely with continued treatment.
That rule prevents an ineffective medicine from being continued indefinitely. It is not a promise that early responders will maintain a particular result.
Safety and tolerability
Common adverse reactions include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhoea. The bupropion component creates seizure, blood-pressure, and neuropsychiatric considerations. The label has a boxed warning about suicidal thoughts and behaviours associated with antidepressant medicines in children, adolescents, and young adults; Contrave is not approved for paediatric use.
Contrave is contraindicated in several situations, including uncontrolled hypertension, seizure disorders, chronic opioid use, and pregnancy. The complete current label—not a summary—should guide screening.
Cardiovascular evidence: why LIGHT cannot be read as reassurance
The LIGHT trial enrolled thousands of participants, but it was terminated early after interim results were publicly disclosed. The published report concluded that the trial did not provide a definitive assessment of cardiovascular safety. Point estimates from incomplete interim data should not be presented as proof of no increased risk.
Price and access
Prices, savings programmes, insurer rules, and marketed brands change. Obtain a current itemised quote and verify eligibility directly. This hub uses regulator and official price records for country claims; it does not treat coupon marketing as a stable price.